FDA Approves Amneal’s Epinephrine Vials for Emergency and Hospital Use

Amneal Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved its epinephrine injection USP, 1 mg/mL, in both single-dose (1 mL) and multi-dose (30 mL) vial formats. The medication is a cornerstone of emergency care, widely used in hospitals, emergency departments, and acute care facilities across the United States.

Epinephrine remains one of the most essential drugs in critical care settings, used to treat life-threatening allergic reactions and manage severe hypotension. By securing FDA approval for both vial presentations, Amneal is expanding availability of this vital therapy at a time when healthcare providers continue to seek reliable, cost-effective supply options.

“Epinephrine is one of the most important and widely used emergency medicines in healthcare,” said Arash Dabestani, Pharm.D., Senior Vice President of Institutional at Amneal. He emphasized that the launch of both single- and multi-dose vial options reinforces the company’s commitment to ensuring consistent access to essential medications across U.S. hospitals and clinics.

Epinephrine is a non-selective alpha and beta adrenergic agonist and is considered first-line treatment for severe allergic reactions, including anaphylaxis triggered by foods, insect stings, medications, and other allergens. The 1 mg/mL formulation is also indicated for adult patients experiencing hypotension associated with septic shock, helping increase mean arterial blood pressure in critical situations.

As with all systemic epinephrine use, adverse reactions are possible. Common side effects include anxiety, restlessness, tremors, sweating, palpitations, nausea, and respiratory difficulty. These reactions often occur even at standard therapeutic doses and may be more pronounced in patients with underlying cardiovascular conditions, hypertension, or hyperthyroidism.

The approval comes amid steady demand for epinephrine in clinical settings. According to IQVIA data, U.S. annual sales of single- and multi-dose epinephrine vials reached approximately $118 million for the 12-month period ending October 2025. Amneal’s entry into the market is expected to support supply stability and provide an additional source of this critical emergency medication.

With this regulatory milestone, Amneal continues to expand its institutional portfolio, contributing to broader efforts to maintain reliable access to foundational therapies used daily in hospital and emergency care.